ZENITH TO MARKET SUSTAINED-RELEASE VERAPAMIL UNDER DEAL WITH SEARLE
Executive Summary
ZENITH TO MARKET SUSTAINED-RELEASE VERAPAMIL UNDER DEAL WITH SEARLE, maker of the brand name verapamil product Calan SR. Zenith announced March 8 that it expects to begin shipping 180 mg and 240 mg sustained-release verapamil HCl in the U.S. immediately. The calcium channel blocker will be made for Zenith by Knoll parent BASF under the Knoll NDA for its sustained-release verapamil, Isoptin SR.